Sign in
Not yet recruitingPhase 3

Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5

Key facts

Who runs it
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Where
China3 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 3
People taking part
525 people, planned
Starts
20 Nov 2026
Expected to end
31 Dec 2030
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • sintilimab+IBI310+chemotherapy
  • sintilimab+chemotherapy
Record updated
17 November 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Aged 18-75 years
  • Histologically confirmed advanced gastric or gastroesophageal junction adenocarcinoma without prior systemic therapy
  • HER2-negative status
  • At least one measurable or evaluable lesion per RECIST v1.1
  • PD-L1 CPS <5, assessed using the PD-L1 IHC 22C3 assay on pretreatment tumor tissue and confirmed by a local or central laboratory
  • ECOG PS 0-1
  • Life expectancy ≥3 months

Who cannot take part

  • Unresolved Grade >1 toxicity from prior anticancer therapy, with protocol-defined exceptions
  • Known DPD deficiency or prior Grade ≥3 fluoropyrimidine-related mucosal toxicity
  • Intestinal obstruction within 28 days before treatment, unless surgically resolved or completely recovered
  • Active tumor bleeding
  • Grade ≥3 hypersensitivity to monoclonal antibodies or chemotherapy components
  • History of seizures, CNS metastases, spinal cord compression, or meningeal metastases
  • Clinically significant cardiovascular or cerebrovascular disease
  • History of severe toxicity requiring permanent discontinuation of immune checkpoint inhibitors or study-related treatment
  • History of noninfectious enteritis requiring corticosteroids within 1 year before treatment
  • Uncontrolled bleeding, bleeding tendency, severe non-healing wounds, ulcers, fractures, or high-risk varices or portal hypertension
  • Pregnant or breastfeeding women, or those planning pregnancy within 6 months after treatment
  • Severe gastrointestinal obstruction or difficulty swallowing tablets

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This is a multicenter, randomized, controlled Phase III clinical study designed to evaluate the efficacy and safety of sintilimab plus ipilimumab N01 and chemotherapy compared with sintilimab plus chemotherapy as first-line treatment for patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with a programmed death-ligand 1 (PD-L1) combined positive score (CPS) of less than 5.

Read full original descriptionShow less

Eligible patients will be randomly assigned to receive either sintilimab plus ipilimumab N01 and chemotherapy or sintilimab plus chemotherapy. The study aims to determine whether the addition of ipilimumab N01 to sintilimab plus chemotherapy can improve clinical outcomes in this patient population while evaluating the safety of the combination regimen.

The 2 groups in the trial

  • Experimental ArmTreatment being tested

    Sintilimab Plus Ipilimumab N01 and Chemotherapy

    Treatment: sintilimab+IBI310+chemotherapy

  • Active ComparatorExisting treatment, for comparison

    Sintilimab Plus Chemotherapy

    Treatment: sintilimab+chemotherapy

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Patients With PD-L1 CPS <5 Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Controlled, Multicenter, Phase III Clinical Study
Criteria questions
Built from NCT07942285, who can take part
Record updated
17 November 2026